IN8BIO, INC. Files 8-K: Shareholder Vote & Financials
Ticker: INAB · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, sec-filing
TL;DR
IN8BIO filed an 8-K on June 12, 2024, covering shareholder votes and financial updates.
AI Summary
On June 12, 2024, IN8bio, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders. The filing also includes other events and financial statements and exhibits. The company, formerly known as Incysus Therapeutics, Inc., is incorporated in Delaware and is in the biological products sector.
Why It Matters
This filing provides crucial updates on IN8bio's corporate governance and financial reporting, which are important for investors to assess the company's current status and future direction.
Risk Assessment
Risk Level: low — This is a routine SEC filing (8-K) reporting on corporate events and financial statements, not indicating immediate operational or financial distress.
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- Incysus Therapeutics, Inc. (company) — Former company name
- June 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39692 (identifier) — SEC file number
FAQ
What specific matters were submitted to a vote of IN8bio's security holders?
The filing indicates the submission of matters to a vote of security holders but does not specify the exact nature of these matters in the provided text.
When was IN8bio, Inc. formerly known as Incysus Therapeutics, Inc.?
The company's name was changed from Incysus Therapeutics, Inc. on May 10, 2018.
What is IN8bio's primary business sector?
IN8bio, Inc. is in the Biological Products (No Diagnostic Substances) sector, SIC code 2836.
What is the principal executive office address for IN8bio, Inc.?
The principal executive offices are located at 350 5th Avenue, Suite 5330, New York, New York 10118.
What is the filing date of this 8-K report?
The 8-K report was filed as of June 13, 2024, with the earliest event reported on June 12, 2024.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-06-13 16:07:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d774911d8k.htm (8-K) — 33KB
- d774911dex991.htm (EX-99.1) — 18KB
- g774911g0613192124867.jpg (GRAPHIC) — 2KB
- 0001193125-24-160703.txt ( ) — 185KB
- inab-20240612.xsd (EX-101.SCH) — 3KB
- inab-20240612_lab.xml (EX-101.LAB) — 18KB
- inab-20240612_pre.xml (EX-101.PRE) — 11KB
- d774911d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated June 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: June 13, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)